Hormonally-regulated proteins in breast secretions are markers of target organ sensitivity by Harding, C et al.
Oestrogen is the major steroid hormone which promotes normal
breast epithelial cell growth and is believed to be important in the
development of human breast cancer (Key and Pike, 1988). Early
oophorectomy reduces the risk of breast cancer (Bullbrook et al,
1986; MacMahon et al, 1986; Key and Pike, 1988) and the admin-
istration of exogenous oestrogens increases the risk of the disease
(Bergkvist et al, 1989; Hunt et al, 1987). Despite extensive study,
however, little conclusive evidence has been published that serum
oestrogen levels predict an individual’s breast cancer risk. Plasma
levels of oestrogen fall after the menopause whilst breast cancer
risk rises in the same age group (Key and Pike, 1988). Other
hormones may also influence the breast epithelium since low
urinary and serum androgens are associated with increased breast
cancer incidence (Zumoff, 1988), whilst hypophysectomy
prevents the carcinogenic effects of oestrogen on the murine
female breast (Lippsett and Bergenske, 1960).
Since serum levels of oestrogen in women at risk or with breast
cancer are similar to age-matched controls (MacMahon et al,
1986; Key and Pike, 1988; Zumoff, 1988), it is possible that
increase in the sensitivity of the breast epithelium contributes to
the risk of breast cancer. Certain breasts may be inherently more
sensitive to oestrogens than others.
Both oestrogen and androgens are concentrated by the breast
(Ernster et al, 1987; Petrakis et al, 1987). In the post-menopausal
breast tissue oestrogen levels are 40 times plasma levels and are
equivalent to levels found in the premenopausal breast (Ernster et
al, 1987; Petrakis et al, 1987).
Nipple aspirates (breast secretions) can be obtained by gentle
breast compression or by applying negative pressure to the nipple
using a Sartorius cup (Petrakis et al, 1981, 1987; Ernster et al,
1987). This nipple fluid represents secretion pooled in the lactif-
erous sinuses and proximal ducts. Such nipple aspirates (NA) can
be produced from 70% of premenopausal and 40% of post-
menopausal Caucasian women in our own and others’ experience
(Petrakis et al, 1981, 1987; Ernster et al, 1987; Wrensch et al,
1990).
A number of authors (Petrakis, 1986; Sanchez et al, 1992;
Petrakis et al, 1993) have investigated breast duct epithelial secre-
tions to determine the value of measurement of the chemical compo-
nents in explaining the pathophysiology of breast conditions.
The breast epithelium responds to hormonal stimulation by
producing a series of specific proteins and inhibiting production of
others. The addition of oestrogen to the medium of MCF7 breast
cancer cell lines has demonstrated that examples of oestrogen-
induced proteins are pS2 and cathepsin D (Brown et al, 1984;
Cavailles et al, 1988, 1989; Weaver et al 1988), whereas cyst
protein 15 (CP15) and apolipoprotein D (Apo D) are oestrogen-
inhibited but androgen-stimulated (Chalbos et al, 1987;
Haagensen et al, 1990; Simard et al, 1990). Oestrogens markedly
reduce Apo D secretion by ZR-75-1 and MCF-7 breast cancer cell
lines: an effect reversed by androgens and anti-oestrogens
(Chalbos et al, 1987; Simard et al, 1990).
Simard et al have shown that levels of both CP15 and Apo D
secreted into the medium of cancer cell lines relate closely to the
proliferative activity of the cell line, levels increasing when the
cells are quiescent (Chalbos et al, 1987; Haagensen et al, 1990;
Simard et al, 1990).
To attempt to produce a physiological measure of hormonal
stimulation of the female breast (i.e. target organ sensitivity) we
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Correspondence to: NJ Bundredhave measured all four proteins in NA from women with normal
breasts, women with benign disease and women with breast pain
treated with goserelin and tamoxifen. To confirm the oestrogen-
responsiveness of the proteins measured we have also assessed the
effect of hormone replacement therapy (HRT) on the concentra-
tions of the four proteins in sequential nipple secretions. We show
that, in general, oestrogen-stimulation is associated with an
increase in pS2 and a decrease in Apo D and CP15.
MATERIALS AND METHODS
Patients
Women with no breast disease (n = 63; age range 21–68 years),
benign breast disease (n = 53; age range 20–61 years) and breast
pain (n = 18; age range 24–39 years) who attended symptomatic
breast clinics at the University Hospital of South Manchester were
studied. In the Palatine Centre, Manchester 26 women (age range
40–69 years), who were about to commence HRT, were recruited
from the Menopause Clinic. All 26 women about to start HRT
(combined HRT, n = 16; oestrogen only, n = 10) were self-referrals
and had no intercurrent breast disease. All oral HRT preparations
provided between 0.625 mg and 2.0 mg oestradiol daily or 50 mg
oestradiol topically. All women gave informed consent. The study
was approved by the Ethics Committee of the University Hospital
of South Manchester and detailed information of reproductive
status, history of breast disease, menopausal status, lactation and
last menstrual period was provided by all women.
All premenopausal women had regular menstrual cycles lasting
between 24–33 days and none (apart from the HRT group) were on
medication likely to alter pituitary or ovarian function from base-
line. There were no significant differences in mean age or repro-
ductive history between the women with or without benign breast
disease.
Benign breast disease was diagnosed from radiographic, echo-
graphic, cytological and histological studies. Among women with
benign disease, 16 were post-menopausal, of whom eight had duct
ectasia, three had a fibroadenoma, and miscellaneous cases (e.g.
fibroadenosis), 36 were premenopausal, of whom 18 had breast
pain, 11 had duct ectasia, four had breast cysts and three had fibro-
cystic masses. Women with spontaneous nipple discharge were
excluded from the study. Women with mastalgia completed breast
pain charts confirming cyclical mastalgia (defined as severe pain,
unresponsive to evening primrose oil, for a minimum of 7 days per
cycle) for a minimum of 4 months. Women meeting these criteria
were offered treatment with goserelin or tamoxifen as appropriate.
There were 35 premenopausal and 28 post-menopausal women
identified from the same clinics who had no evidence of breast
disease. They presented with symptoms of breast lumps, nipple
changes or concerns regarding potential risk of breast cancer 
(e.g. family history), but were found, after clinical assessment and
radiological investigations, to have no abnormality and no
increased breast cancer risk.
Breast fluid collection
Nipple secretion specimens were obtained from each breast by
bimanual, four quadrant compression, followed by Sartorius cup
suction (Petrakis et al, 1981) if compression failed. Attempts were
made to obtain specimens from both breasts. Secretion specimens
were collected before any diagnostic study or surgical procedure
was carried out on the breast. The fluid was collected into capillary
tubes. The volume of neat nipple secretion was calculated by
multiplying the length (in mm) of nipple fluid in the tube by the
cross-sectional area of the lumen of the capillary tube. Volumes
obtained varied from 0.67 to 106 ml. The capillary tubes were
transferred into 1.5 ml test tubes and centrifuged at 6500 rpm for 
5 min. Phosphate-buffered saline (PBS) solution was then added to
the nipple secretion to a known dilution (between 1:25 and 1:300).
The diluted specimen was then frozen at –20°C for later analysis.
Assays
Apolipoprotein D (Apo D) was measured using a competitive
polyclonal radioimmunoassay previously described by Haagensen
and using the principles of Yalow and Berson (Sanchez et al,
1992). Fifty microlitres of standard Apo D or specimens were
incubated with 200 ml of 125I-Apo D and 200 ml of rabbit anti-
human Apo D serum (1:5000) for 4 h at 4°C. Apo D–antibody
complexes were then precipitated by incubating the reaction
mixture with 50 ml of donkey anti-rabbit coated microcrystalline
cellulose (sac-cel) for 30 min at room temperature. Three milli-
litres of wash solution (0.9% sodium chloride and 0.05% Tween-
20) were then added and the reaction mixture centrifuged at 
2500 rpm for 20 min at 10°C. The supernatant was then discarded
and bound 125I-Apo D–antibody complex was then counted using a
gamma scintillation counter. The concentrations of Apo D in the
specimens were inversely proportional to the radioactive counts
obtained for the specimens. These concentrations were calculated
from a standard curve plotted as % B/Bo versus log10 standard
concentration, where B = bound counts and Bo = maximum counts
bound. The standard curve was constructed using standard solu-
tions of 10 000, 5000, 1000, 500 and 250 ng ml–1 of Apo D. The
sensitivity of the assay was 80 ng ml–1. Intra-assay variation was
less than 9% over the full working range and inter-assay variation
was 12.4%, 8.2% and 9.7% at levels of 620 ng ml–1, 1250 ng ml–1
and 3030 ng ml–1 respectively. Breast samples were analysed in
duplicate (at two dilutions, 1:10 000 and 1:50 000) and the average
concentration for each specimen was calculated. The Apo D
concentration in the original, undiluted sample was then obtained
and expressed in g l–1. Purified apolipoprotein D and rabbit anti-
apolipoprotein D were a kind gift from Dr DA Haagensen,
Sacramento, USA.
Gross cystic disease fluid protein (CP15) was quantified using a
novel competitive enzyme immunoassay in which purified CP15
(coated on to microtitre wells) and CP15 in standard or patient
sample compete for binding to rabbit anti-CP15. A 96-well plate
was coated with 100 ml of 250 ng ml–1 CP15 in azide PBS solution
and incubated at 4°C overnight. The coating was then discarded
and each well was then washed with 200 ml of wash buffer twice
and the buffer discarded. One hundred microlitres of bovine-
specific antigen (BSA) in PBS was added to each well and the plate
was again incubated overnight at 4°C and the BSA was discarded
the next day. Standards of 125, 62, 31, 15, 7, 4 and 2 ng ml–1 were
used to construct the standard curve. Fifty microlitres of standards
and specimens were then transferred to the plate wells in triplicate,
and after adding 50 ml of 1:10 000 anti-CP15 to each well (except
those wells allocated to test non-specific binding which were filled
with 100 ml dilution buffer only), the plates were then incubated for
a further 4 h at 4°C. The plate contents were again then discarded
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IgG conjugate was added to each well and the plate was again incu-
bated overnight at 4°C. After washing with wash buffer and citrate
buffer and the contents discarded, 100 ml of OPD solution was then
added to each plate and the plate stored in the dark for 5 min at
room temperature. The colour reaction was then stopped with 100
ml 1M hydrochloric acid. The plate was read using a 492 nm filter
on a plate reader. The standard curve was plotted as log [CP15] ng
ml–1 against mean absorbance and the CP15 concentrations for the
specimens were then calculated and expressed in ng ml21.
Purified CP15 and rabbit anti-CP15 were a kind gift from Dr DA
Haagensen, Sacramento, USA. The interassay variation was 15%.
pS2 was measured using a commercially available radio-
immunoassay kit (CIS UK Ltd). Each specimen, standard and
control was analysed in duplicate and results expressed in pmol
ml–1. The interassay variation was 7.27% and the intraassay varia-
tion was 3.03%.
Cathepsin D (cat D) was also measured using a commercially
available radioimmunoassay kit (CIS UK Ltd). Each specimen,
standard and control was analysed in duplicate and results
expressed in fmol ml–1. The interassay variation was 3.64% and
the intra-assay variation was 5.67%.
Total protein was measured by a modification of the Bradford
method. Standards were first prepared using BSA in phosphate
buffered saline PBS at dilutions of 0.002–0.02 mg ml–1. Samples
were prepared by making 1:100 dilutions of the original diluted
samples using PBS, giving assay samples at dilutions of
1:2500–1:30 000. Using a 96-well, flat-bottomed plate, 75 ml of
sample or standard was mixed with 75 ml dye reagent concentrate
(Bio-Rad, Munich) diluted to 1:5 with distilled water. After 5 min
the protein concentration was calculated from a standard curve by
reading the OD for each sample using a 595 nm filter on a plate
reader. Total protein was calculated in g l–1. The interassay varia-
tion was 8.2% and the intraassay variation was 6.2%.
Statistical analysis
Non-parametric statistical analysis of between-group (benign
versus normal) differences was assessed using Mann–Whitney 
U-test and Kruskal–Wallis tests. Sequential changes in secretion
protein levels were compared using the Wilcoxon test. Data are
presented as median ± interquartile range. Parametric data was
analysed using the paired t-test.
RESULTS
Effect of the menopause on secretion of proteins
Cat D was higher in NA from normal premenopausal women
compared to post-menopausal women (P < 0.02) (Figure 1 and
Tables 1 and 2) There was no difference between NA pS2 concen-
trations from premenopausal compared to post-menopausal
women with normal breasts (Tables 1 and 2). Apo D and CP15
were lower in breast secretions from premenopausal women
compared to the post-menopausal group (Tables 1 and 2 and
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Figure 1 Levels of cathepsin D in nipple aspirates from normal
premenopausal women (n = 35) were significantly higher than nipple
aspirates from post-menopausal women (n = 28, P ≤ 0.02; Mann–Whitney U-
test). Data are shown with thick horizontal line representing median value
and thinner horizontal lines the interquartile ranges
Table 1 Nipple secretion concentrations in premenopausal women
Normal Benign Cyclical mastalgia
Before After After
treatment goserelin tamoxifen
Number 35 36 18 9 9
Median [pS2] 8.5 15.2 17.2 6.53 4.25
Range (1.4–107.4) (0.2–104.9) (0.9–155.9) (0.12–38.7) (0–25.03)
(ng mg–1 protein)
Median [Cat D] 4.7 4.1 5.9 3.2 3.5
Range (0.6–19.1) (0–27.9) (1.7–91.1) (1.0–22.6) (0.1–35.6)
(fmol mg–1 protein)
Median [Apo D] 159 178.2 47.15 525 303.5
Range (12–1833) (8.9–791.6) (8.9–339.9) (34.4–861.3) (76.5–485.2)
(mg mg–1 protein)
Median [CP15] 33.05 25.44 29.1 99.3 not done
Range (0–188.9) (0–183.4) (0.8–169) (35.5–146.1)
(mg mg–1 protein)
Nipple aspirate pS2 concentrations were significantly higher and Apo D concentrations were significantly lower in women with cyclical mastalgia compared with
women with normal breasts (P < 0.05). Treatment with goserelin and tamoxifen significantly suppressed concentrations of pS2 (P < 0.02) and increased Apo D
and CP15 (P < 0.03 and P < 0.05 respectively) in breast secretions. No significant effect was seen on cat D.Figure 2).
Analysis of NA from normal women revealed pS2 and Apo D
levels inversely correlated (P ≤ 0.05; Spearman’s correlation 
coefficient). Amongst women with benign breast disease, pS2
concentrations in NA were higher in premenopausal (median 
15.2 ng mg–1 protein, range 0.2–104.9 ng mg–1 protein) compared
to post-menopausal secretions (median 2.9 ng mg–1 protein, range
0.1–7.7, P < 0.002), but NA levels of cat D, Apo D and CP15 did
not differ between premenopausal and post-menopausal women
with benign disease (Tables 1 and 2).
In 35 women who provided NA bilaterally there was a good
correlation of both Apo D and pS2 between breasts (r = 0.9; 
P ≤ 0.001 for both). Additionally, 18 women gave sequential
nipple aspirates at least 1 month apart whilst not on any therapy
and levels did not change significantly between the two time
points (r = 0.99 pS2, r = 0.94 Apo D). Geometric transformation of
data revealed that levels in control women could vary as much as
31% (relative risk (RR) 1.03; 95% confidence interval (CI)
0.81–1.31) for pS2 and 71% (RR 1.06; 95% CI 0.66–1.71) for Apo
D between women.
Comparison of normal and benign breast disorders
In the premenopausal group, there were no significant differences
in NA protein concentrations between normal women and those
with benign breast disease (Table 1). Post-menopausal women
with benign breast disease had lower Apo and concentrations
compared to normal women (P < 0.007 and P < 0.05 respectively;
see Tables 1 and 2). pS2 and cat D did not differ between the
groups in post-menopausal women.
In patients with cyclical mastalgia, NA pS2 concentrations were
significantly higher than in normal premenopausal women (Table
1, P < 0.05). Apo D concentrations were significantly lower in
women with cyclical mastalgia compared with normal women
(Table 1, P < 0.04).
Cyclical mastalgia: effect of treatment with goserelin
and tamoxifen
Treatment of patients with cyclical mastalgia with either goserelin
or tamoxifen for 3 months significantly reduced pS2 to a median of
6.5 ng mg–1 protein and 4.3 ng mg–1 protein respectively (P < 0.02
and P < 0.05, Figure 3A). These treatments increased NA Apo D
concentrations to 525 mg mg–1 protein and 303.5 mg mg–1 protein
respectively (P < 0.03 and P < 0.05, Figure 3B and Table 1). The
300% decline in pS2 and the tenfold increase in Apo D detected
with goserelin treatment was highly correlated (r = –0.934, 
P < 0.001) and contrasted with the small changes in the levels of the
same proteins in sequential samples for control women. The ratio
of pS2 to Apo D was significantly reduced from a median of 525 ng
mg–1 (range 50–2500 ng mg–1) to 50 ng mg–1 (0–410 ng mg21, P <
0.008). NA concentrations of CP15 also significantly increased
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Table 2 Nipple secretion concentrations in post-menopausal women before and after treatment with HRT
Normal Benign Hormone replacement therapy
Before After 6 months
Number 28 16 26 25
Median [pS2] 9.1 2.9 9.6 35.8
Range (1.4–148.9) (0.1–7.7) (0–130.71) (10.4–130)
(ng mg–1 protein)
Median [Cat D] 0.1 0.1 0.1 1.11
Range (0–5.8) (0.2–9.3) (0.1–6.1) (0.1–61)
(fmol mg–1 protein)
Median [Apo D] 257 140.5 193.5 167.5
Range (59–4314) (27.2–1670.7) (10.5–612.0) (0–442.5)
(mg mg–1 protein)
Median [CP15] 53.5 5.61 50.6 71.0
Range (0.2–159.1) (0–68.86) (0.004–159.1) (0–212.7)
(mg mg–1 protein)
Proteins in nipple secretions did not differ between normal breasts and cases of benign breast disease. HRT significantly increased pS2 (P < 0.001) and











Figure 2 Levels of apolipoprotein D in nipple aspirates from normal post-
menopausal women with no breast disease (n = 28) were significantly higher
than levels from normal premenopausal women (n = 35, P ≤ 0.02)after treatment with goserelin (P < 0.05, Table 1 and Figure 3C).
Neither treatment altered concentrations of NA cat D. Three
months’ treatment with goserelin reduced serum oestrogen concen-
trations from 231.2 pmol l–1 (59–569 pmol l–1) to 81.3 pmol l–1
(40–153 pmol l–1, P < 0.009).
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Figure 3 The effect of goserelin (an LHRH agonist) treatment on nipple secretion levels of (A) pS2, (B) Apo D, (C) CP15 (otherwise known as GCDFP15) and
(D) Cat D levels. Nine premenopausal women with breast pain underwent treatment with goserelin for 3 months. Prior to therapy nipple aspirate levels of pS2
were significantly higher and Apo D levels significantly lower than levels in aspirates from normal premenopausal breasts (see Table 1). On treatment a
significant sequential fall in pS2 aspirate levels was mirrored by a significant rise in Apo D and CP15 levels. The correlation between pS2 and Apo D aspirate
levels in the individual women was highly significant (r = –0.93; P ≤ 0.001)Effect of HRT
Secretions were obtained before, and after 6 months of HRT in
25/26 women (one individual failed to produce secretion after 6
months, HRT). Nipple aspirate concentrations of pS2 increased
fourfold (P < 0.001, Table 2 and Figure 4) and Apo D fell signifi-
cantly (P < 0.05) on HRT. Total protein levels in NA did not alter
significantly on any treatment.
DISCUSSION
Seventy per cent of premenopausal and 40% of post-menopausal
women (Harding et al, 1996) produced NA, a yield which
compares with 42% and 17% respectively reported by Wrensch et
al (1990). These investigators used Sartorius cup suction, whereas
we found manual compression to be equally effective. The volume
of secretions varied widely: it did not increase with sequential
sampling suggesting that the collection of secretions did not stim-
ulate increased fluid production.
Proteins which are regulated by sex steroids in human breast
cancer cells in vitro are detectable in most NA. The individual
values vary widely reflecting differences in circulating hormone
concentrations between women. When serum oestrogen concen-
trations were reduced by goserelin, nipple secretion concentrations
of pS2 fell, whilst those of Apo D increased. Similar changes were
seen with the anti-oestrogen tamoxifen and the opposite effect
occurred when HRT was administered. These data suggest that
pS2 and Apo D may be used to reflect the effect of oestrogens on
the breast. However, changes in concentrations of cat D and CP15
were not so clear-cut.
Differences were seen in protein concentrations between normal
pre- and post-menopausal women. Consistent with the post-
menopausal fall in serum oestradiol concentrations, NA Cat D
levels were lower and Apo D and CP15 levels were higher. The
large overlap of concentrations of all measured proteins between
pre- and post-menopausal women may be related to the reported
high oestrogen concentrations in breast tissue and NA in post-
menopausal women (Ernster et al, 1987). In women with benign
disease, there was a reduction in both pS2 and Cat D after the
menopause: however, Apo D and CP15 did not show the expected
increase in concentrations, which may reflect the fact that breast
aromatization of oestrogen continues after the menopause and
causes continued suppression of Apo D and CP15 secretion
although not stimulating an increase in pS2 and Cat D levels.
We have looked for biomarkers of target organ sensitivity to
hormones and hypothesized that benign disorders might be related
to increased sensitivity to oestrogen. Although we found higher
concentrations of NA pS2 were present in premenopausal women
there were no differences in NA concentrations of other proteins
studied in premenopausal women. In post-menopausal women
Apo D and CP15 were significantly lower in the benign group
which may reflect heightened sensitivity to oestrogen suppression
by low levels of oestradiol in women with benign disorders.
The best evidence for our hypothesis was found in the women
with cyclical mastalgia where breast pain and tenderness can be
relieved either by reducing serum oestradiol concentrations by
ovarian suppression or by using anti-oestrogens suggesting that
this condition is related to sensitivity of the breast to oestradiol. No
consistent differences in serum oestradiol concentrations between
women with and without cyclical mastalgia have been demon-
strated (Ernster et al, 1987). Increased target organ sensitivity to
oestradiol is supported by our data in that NA pS2 concentrations
were significantly higher and Apo D concentrations were lower in
women with mastalgia compared to those without (Table 1).
Treatment of these women with goserelin resulted in relief of pain
and a mean reduction of oestradiol of two- to eightfold. PS2
concentrations declined threefold and Apo D increased tenfold
after 3 months of treatment suggesting that the synthesis of these
proteins was controlled by oestrogen. This is supported by similar
responses to tamoxifen (Table 1). The elevated NA levels of pS2
and suppressed Apo D and CP15 found in these women indicate
that the condition is caused by increased target organ sensitivity of
the breast to oestrogen and the changes in pS2, Apo D and CP15
mirrored symptomatic relief of the pain. HRT increased NA pS2
levels over a 3-month period, whereas Cat D levels were unaltered.
Concentrations of NA Cat D did not decline after goserelin or
tamoxifen treatment and Cat D concentrations may be influenced
by factors distinct from those governing pS2 production (Cavailles
et al, 1989; Rajah et al, 1996). In cases where it is unclear whether
pain is originating from the breast or chest wall behind the breast,
measurement of nipple aspirate pS2 levels may prove useful to aid
diagnosis.
The two cyst protein markers CP15 and Apo D proved better
markers of anti-oestrogen therapy as their levels rose with treat-
ment. However, it is notable that on HRT NA pS2 concentrations
rose and Apo D concentrations fell.
Although proliferating breast cancer cell lines produce pS2 and
Cat D in response to oestrogen (Cavailles et al, 1989), in vitro Cat
D production is also regulated by growth factor stimulation
(Cavailles et al, 1989) and the failure to show changes in NA Cat
D levels in women with cyclical mastalgia may reflect differences
between benign and malignant epithelium or that the therapy
altered growth factor production in a different direction. Breast
tissue taken at comparable times during the menstrual cycle of
young women shows marked differences in proliferative indices
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Figure 4 The effect of hormonal replacement therapy (oestrogen alone, or
oestrogen and progesterone) on the oestrogen induced protein pS2 in nipple
aspirates. Sequential analysis in 26 women before and after 6 months on
therapy revealed a significant rise in pS2 levels (P ≤ 0.001)(Potten et al, 1988) and there is a wide variation in the proliferative
response of normal breast tissue of different women when
implanted into nude mice treated with oestradiol (Potten et al,
1988). Cathepsin D (but not pS2) concentrations in NA may
reflect background proliferative activity which is also influenced
by growth factors secreted locally (e.g. epidermal growth factor)
(Cavailles et al, 1989).
In the group of normal post-menopausal women who were
commencing HRT, oestrogen administration resulted in a signifi-
cant increase of NA pS2 and decrease of Apo D after 6 months
treatment demonstrating that these two proteins are the optimal
markers to use for studying the oestrogenicity/anti-oestrogenicity
of biological compounds. NA Cat D and CP15 which did not
change are not sufficiently sensitive markers of changes in serum
oestradiol.
With the current search for chemopreventative agents to reduce
breast cancer incidence, non-invasive markers of the anti-
oestrogen and antiproliferative effect of drugs which are being
tested are necessary in these short-term studies. Apo D would
appear to best fit this requirement as Apo D levels rise in response
to anti-oestrogen therapy and also in response to reduced cell
proliferation (Simard et al, 1990). The measurement of NA Apo D
after 3-month therapy with proposed anti-oestrogens (e.g. phyto-
oestrogens) should inform their effect on the breast and provide
evidence of their likely effectiveness over a longer time period.
This is the first time an effect of tamoxifen on the normal breast
has been demonstrated, and provides a non-invasive method of
assessing the effect of anti-oestrogens on the normal breast where
this endocrine therapy is being prescribed for breast cancer
prevention. Since only 50% of women will have their tumours
prevented by anti-oestrogen therapy (Early Breast Cancer Trialists
Collaborative Group, 1992) it will be important to develop a
method to monitor the effects of the drug on the breast, so that
non-responders can be considered for alternative or additional
therapy.
We believe sequential measurement of NA levels of pS2 and
Apo D will fulfil this function and may predict which women will
benefit from anti-oestrogen chemoprevention therapy. The
response to breast pain therapy by anti-oestrogens was predicted
by a fall in pS2 and a rise in Apo D. Measurement of nipple secre-
tion proteins is a useful pretreatment marker of women’s indi-
vidual response to therapy and may prove a valuable intermediate
end point of effect in the ongoing chemopreventative trials of
tamoxifen. It will also prove a new non-invasive method of
assessing the effect of new anti-oestrogens (e.g. ICI 182 and
Raloxifene) on the normal human breast.
In conclusion, we have developed a non-invasive measure of
breast responsiveness to oestrogen which may prove valuable in
assessing an individual woman’s risk from breast cancer in rela-
tion to hormonal stimulation.
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